These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23416534)

  • 21. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
    Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
    Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
    Ott MC; Costain WJ; Mishra RK; Johnson RL
    Peptides; 2000 Feb; 21(2):301-8. PubMed ID: 10764960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The First Negative Allosteric Modulator for Dopamine D
    Rossi M; Fasciani I; Marampon F; Maggio R; Scarselli M
    Mol Pharmacol; 2017 Jun; 91(6):586-594. PubMed ID: 28265019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.
    Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Barton HA; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
    Pharm Res; 2016 Apr; 33(4):1003-17. PubMed ID: 26718955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
    Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
    Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats.
    Franke RT; Tarland E; Fink H; Pertz HH; Brosda J
    Psychopharmacology (Berl); 2016 Aug; 233(15-16):3041-50. PubMed ID: 27317020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.
    Ye N; Song Z; Zhang A
    Curr Med Chem; 2014; 21(4):437-57. PubMed ID: 24164194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D
    Vanover KE; Davis RE; Zhou Y; Ye W; Brašić JR; Gapasin L; Saillard J; Weingart M; Litman RE; Mates S; Wong DF
    Neuropsychopharmacology; 2019 Feb; 44(3):598-605. PubMed ID: 30449883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel l-prolyl-l-leucylglycinamide (PLG) tripeptidomimetics based on a 2-azanorbornane scaffold as positive allosteric modulators of the D
    Sampaio-Dias IE; Sousa CA; García-Mera X; Ferreira da Costa J; Caamaño O; Rodríguez-Borges JE
    Org Biomol Chem; 2016 Nov; 14(47):11065-11069. PubMed ID: 27830864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
    Kapur S; McClelland RA; VanderSpek SC; Wadenberg ML; Baker G; Nobrega J; Zipursky RB; Seeman P
    Neuroreport; 2002 May; 13(6):831-5. PubMed ID: 11997696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical findings with new antipsychotic agents: what makes them atypical?
    Jackson DM; Ryan C; Evenden J; Mohell N
    Acta Psychiatr Scand Suppl; 1994; 380():41-8. PubMed ID: 7914047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.